Home
Resources
Publications
Safety and Efficacy of Sequential i.v. To p.o. Moxifloxacin Versus Conventional Combination Therapies for the Treatment of Community-Acquired Pneumonia in Patients Requiring Initial i.v. Therapy

Safety and Efficacy of Sequential i.v. To p.o. Moxifloxacin Versus Conventional Combination Therapies for the Treatment of Community-Acquired Pneumonia in Patients Requiring Initial i.v. Therapy

Eric Katz, L Scott Larsen, Charles M Fogarty, Kamal Hamed, James Song, Shurjeel Choudhri

J Emerg Med. 2004 Nov;27(4):395-405.

PMID: 15498622

Abstract:

To compare the efficacy of sequential i.v. to p.o. moxifloxacin with ceftriaxone +/- azithromycin +/- metronidazole for the treatment of patients with community acquired pneumonia (CAP), a multi-centered, prospective, randomized, open label study was performed. CAP patients were randomized to moxifloxacin (400 mg/d-at least one i.v. dose) or ceftriaxone (at least one dose of 2 g i.v. q.d. followed by cefuroxime 500 mg p.o. b.i.d.) +/- azithromycin, +/- metronidazole (cephalosporin/macrolide control: CMC). The primary endpoint was clinical response at test-of-cure (TOC) visit. Bacteriological response at TOC was the secondary endpoint. Clinical cure was found in 83.3% (90/108) of moxifloxacin patients and 79.6% (90/113) of control patients. Microbiological responses were 81.8% (18/22) for moxifloxacin and 60.7% (17/28) for CMC patients. Drug-related adverse events occurred in 18.0% of moxifloxacin and 16% of CMC patients. It is concluded that i.v. to p.o. moxifloxacin is as effective as CMC for treatment of CAP and is a reliable alternative antimicrobial therapy.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1029364779	Moxifloxacin Related Compound D		1029364-77-9	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: